Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis

Oncogene volume 21, pages 3149–3161 (2002)Cite this article

Abstract

The human INK4a gene locus encodes two structurally unrelated tumor suppressor proteins, p16INK4a and p14ARF, which are frequently inactivated in human cancer. Whereas p16INK4a acts through engagement of the Rb-cdk4/6-cyclin D pathway, both the pro-apoptotic and cell cycle-regulatory functions of p14ARF were shown to be primarily dependent on the presence of functional p53. Recent reports have also implicated p14ARF in p53-independent mechanisms of cell cycle regulation and apoptosis induction, respectively. To further explore the pro-apoptotic function of p14ARF in relation to functional cellular p53, we constructed a replication-deficient adenoviral vector for overexpression of p14ARF (Ad-p14ARF). As expected, Ad-p14ARF efficiently induced apoptosis in p53/Rb wild-type U-2OS osteosarcoma cells at low multiplicities of infection. Interestingly, Ad-p14ARF also induced apoptosis in both p53-deleted SAOS-2 osteosarcoma cells and HCT116 colon cancer cells with a bi-allelic knock-out of p53 (HCT116-p53−/−). Similarly, adenovirus-mediated overexpression of p14ARF induced apoptosis in p53/Bax-mutated DU145 prostate cancer cells as well as in HCT116 cells devoid of functional Bax (HCT116-Bax−/−). Restoration of Bax expression by retroviral gene transfer in DU145 cells did not further enhance p14ARF-triggered cell death. Infection with Ad-p14ARF induced activation of mitochondrial permeability shift transition, caspase activation and apoptotic DNA fragmentation irrespective of the presence or absence of either Bax or functional cellular p53. Nevertheless, overexpression of the anti-apoptotic Bcl-2 homolog Bcl-xL markedly inhibited p14ARF-induced apoptosis. This may indicate that p14ARF triggers a so far unknown activator of mitochondrial apoptosis which can be inhibited by Bcl-2 but which acts either independently or downstream of Bax. Taken together, this report demonstrates the participation of signaling pathways apart from the p53/Mdm-2 rheostat and Bax in p14ARF-mediated apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Adams JM, Cory S . 1998 Science 281: 1322–1326

  • Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL . 2000 Gene Ther. 7: 1034–1038

  • Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B . 1995 Int. J. Cancer 60: 854–859

  • Bosanquet, Sturm I, Wieder T, Essmann F, Margaret I, Bosanquet M, Head DJ, Dörken B, Daniel PT . 2002 Leukemia 16: in press

  • Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B . 1998 Science 282: 1497–1501

  • Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P . 2001 Lab. Invest. 81: 217–229

  • Carnero A, Hudson JD, Price CM, Beach DH . 2000 Nat. Cell. Biol. 2: 148–155

  • Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M . 1996 J. Virol. 70: 4805–4810

  • Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK . 1995 J. Virol. 69: 7430–7436

  • Crompton M . 2000 J. Physiol. 529: 11–21

  • Daniel PT . 2000 Leukemia 14: 2035–2044

  • Daniel PT, Punn KT, Ritschel S, Sturm I, Holler J, Dörken B, Brown R . 1999 Blood 94: 1100–1107

  • Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K . 2001 Leukemia 15: 1022–1032

  • de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW . 1998 Genes Dev. 12: 2434–2442

  • Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL . 1999 Genes. Dev. 13: 2658–2669

  • Essmann F, Wieder T, Otto A, Muller EC, Dörken B, Daniel PT . 2000 Biochem. J. 346: 777–783

  • Evan GI, Vousden KH . 2001 Nature 411: 342–348

  • Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S . 2001 Oncogene 20: 1033–1041

  • Fatyol K, Szalay AA . 2001 J. Biol. Chem. 276: 28421–28429

  • Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dörken B, Daniel PT . 2001 Oncogene 20: 2749–2760

  • Groth A, Weber JD, Willumsen BM, Sherr CJ, Roussel MF . 2000 J. Biol. Chem. 275: 27473–27480

  • Hengartner MO . 2000 Nature 407: 770–776

  • Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dörken B, Daniel PT . 2001 Int. J. Cancer 92: 805–811

  • Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ . 1997 Proc. Natl. Acad. Sci. USA 94: 12401–12406

  • Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, Yuasa Y . 2000 Int. J. Cancer 87: 654–658

  • Inoue R, Asker C, Klangby U, Pisa P, Wiman KG . 1999 Anticancer Res. 19: 2939–2943

  • Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC . 1998 Proc. Natl. Acad. Sci. USA 95: 4997–5002

  • Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ . 1999 Cancer Res. 59: 2217–2222

  • Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ . 1998 Proc. Natl. Acad. Sci. USA 95: 8292–8297

  • Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ . 1997 Cell 91: 649–659

  • Karayan L, Riou JF, Seite P, Migeon J, Cantereau A, Larsen CJ . 2001 Oncogene 20: 836–848

  • Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC . 1996 Cancer Res. 56: 2422–2427

  • Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A . 2001 Nature 413: 83–86

  • Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K . 1998 Genes Chromosomes Cancer 23: 273–277

  • Li H, Zhu H, Xu CJ, Yuan J . 1998 Cell 94: 491–501

  • Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X . 1997 Cell 91: 479–489

  • Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D . 1995 Cancer Res. 55: 2995–2997

  • Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman SR . 2001 Proc. Natl. Acad. Sci. USA 98: 4455–4460

  • Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H . 2001 Brain Pathol. 11: 159–168

  • Palmero I, Pantoja C, Serrano M . 1998 Nature 395: 125–126

  • Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA . 1998 Cell 92: 713–723

  • Poppe M, Reimertz C, Dussmann H, Krohn AJ, Luetjens CM, Brockelmann D, Nieminen AL, Kogel D, Prehn JH . 2001 J. Neurosci. 21: 4551–4563

  • Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig WD, Henze G, Dörken B, Daniel PT . 2000 Leukemia 14: 1606–1613

  • Quelle DE, Cheng M, Ashmun RA, Sherr CJ . 1997 Proc. Natl. Acad. Sci. USA 94: 669–673

  • Quelle DE, Zindy F, Ashmun RA, Sherr CJ . 1995 Cell 83: 993–1000

  • Radetzki S, Kohne CH, von Haefen C, Gillissen B, Sturm I, Dorken B, Daniel PT . 2002 Oncogene 21: 227–238

  • Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N . 1998 Proc. Natl. Acad. Sci. USA 95: 13194–13199

  • Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW . 1999 Genes Dev. 13: 2670–2677

  • Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA . 1996 Cell 85: 27–37

  • Sherr CJ . 2000 Cancer Res. 60: 3689–3695

  • Simonian PL, Grillot DA, Merino R, Nunez G . 1996 J. Biol. Chem. 271: 22764–22772

  • Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G . 1998 EMBO J. 17: 5001–5014

  • Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT . 1999 J. Clin. Oncol. 17: 1364–1374

  • Sturm I, Papadopoulos S, Hillebrand T, Benter T, Luck HJ, Wolff G, Dörken B, Daniel PT . 2000 Int. J. Cancer 87: 517–521

  • Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT . 2001 J. Clin. Oncol. 19: 2272–2281

  • Tsujimoto Y, Shimizu S . 2000 Cell Death Differ. 7: 1174–1181

  • Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, Borrelli L, Saviozzi S, La Mantia G . 2001 J. Biol. Chem. 276: 14161–14169

  • Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dörken B . 1996 Int. J. Cancer 67: 138–141

  • Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP . 2000 Genes Dev. 14: 2358–2365

  • Weinmann P, Bommert K, Mapara MY, Dörken B, Bargou RC . 1997 Eur. J. Immunol. 27: 2466–2468

  • Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B, Daniel PT . 2001 Blood 97: 1378–1387

  • Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM . 2000 J. Natl. Cancer Inst. 92: 636–641

  • Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B . 2000 Science 290: 989–992

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF . 1998 Genes Dev. 12: 2424–2433

Download references

Acknowledgements

We would like to thank Verena Lehmann and Antje Richter for expert technical assistance, HepaVec AG, Berlin for providing part of the Ad vector components and Dr K Brand, Max Delbrück Center, Berlin for helpful discussions. Moreover, we would like to thank Dr KG Wiman, Dr U Klangby and Dr Mikael Lindström, Karolinska Cancer Center, Stockholm, Sweden for generously providing a cDNA encoding full-length human p14ARF.

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Tumor Immunology, Charité - Campus Berlin-Buch, Humboldt University, Lindenberger Weg 80, Berlin-Buch, 13125, Germany

    Philipp G Hemmati, Bernhard Gillissen, Clarissa von Haefen, Jana Wendt, Lilian Stärck, Bernd Dörken & Peter T Daniel

  2. Department of Radiation Oncology, Charité - Campus Mitte, Berlin, Germany

    Dilek Güner

Authors
  1. Philipp G Hemmati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernhard Gillissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clarissa von Haefen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jana Wendt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lilian Stärck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dilek Güner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bernd Dörken
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter T Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter T Daniel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hemmati, P., Gillissen, B., von Haefen, C. et al. Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis. Oncogene 21, 3149–3161 (2002). https://doi.org/10.1038/sj.onc.1205458

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205458

Keywords

This article is cited by

Search

Advanced search

Quick links